Drug Use Patterns during the COVID-19 Pandemic: A Case Study at Persahabatan General Hospital

  • Fitri Nurhayati Instalasi Farmasi, Persahabatan General Hospital, East Jakarta, Jakarta, 13230, Indonesia
  • Dendhi Bagus Andriyanto Instalasi Farmasi, Persahabatan General Hospital, East Jakarta, Jakarta, 13230, Indonesia
  • Fadhila Putri Instalasi Farmasi, Persahabatan General Hospital, East Jakarta, Jakarta, 13230, Indonesia
  • Rara Merinda Puspitasari Universiti Kuala Lumpur, Royal College of Medicine Perak, Ipoh, Perak, 30450, Malaysia
DOI: https://doi.org/10.35814/jifi.v21i1.1396

Abstract

The COVID-19 pandemic condition has encouraged healthcare practitioners to adapt and constantly work to meet the needs of those who require healthcare, including medication supply. This study aims to provide the drug use patterns prior to and throughout the COVID-19 pandemic. This retrospective descriptive study analyzed the drug use patterns of 10 fast-moving drugs obtained through purposive sampling, as well as all medications listed in COVID-19 guideline therapy at Persahabatan general hospital. The drug use data was derived from the quarterly data from 2019 through the second quarter of 2021. The result showed that there was an increase and variation in the sampled drug usage. The top-ranking classes that have shown an upward trend during the COVID-19 pandemic were Vitamin C 500 mg tablet, Vitamin C 200 mg injection, and Vitamin D3 5000 UI tablet. Meanwhile, non-COVID-19 medicines with reduced use include Cefotaxime 1 g, Cefixime 200 mg, and Docetaxel 20 mg. Therefore, it is necessary to analyze the drug utilization continuously and as frequently as feasible throughout the pandemic and plan in stages. Forecasting demand for medicines is essential for an effective medicinessupply chain, in particular in a pandemic context to avoid shortages or overstock.

References

1. World Health Generation. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. Available from: https://www. who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.

2. Setiadi W, Rozi IE, Safari D, Daningrat WOD, Johar E, Yohan B, et al. Prevalence and epidemiological characteristics of COVID-19 after one year of pandemic in Jakarta and neighbouring areas, Indonesia: A single center study. PLoS One. 2022;17(5 May):1–9.

3. Jorge V-M, Esteban Z-M, Bruno S-A, Yeralin H-F, Pablo D-MJ. Implementation of supply management strategies by the pharmacy service in a general hospital during the COVID-19 pandemic. Explor Res Clin Soc Pharm. 2022;7(July):100161.

4. Dr. Satibi. Manajemen Obat di Rumah Sakit. Manejemen Adminsitrasi Rumah Sakit. 2014;8(5):h: 6-7, 9-10.

5. OMS. Clinical management Clinical management Living guidance COVID-19. 2021B. 2021;(January):16–44.

6. Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: An overview. Eur J Pharmacol. 2020;889(October):173644.

7. Beck M, Buckley J. Managing pharmaceutical shortages during the COVID pandemic: An exploratory analysis of European collective and national government responses. J Med Access. 2022;6.

8. Keputusan Menteri Kesehatan Republik Indonesia. Keputusan menteri kesehatan republik indonesia nomor hk.01.07/menkes/5671/2021 tentang manajemen klinis tata laksana. 2021;3:1–106.

9. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9.

10. Parajuli DR, Khanal S, Wechkunanukul KH, Ghimire S, Poudel A. Pharmacy practice in emergency response during the COVID-19 pandemic: Lessons from Australia. Res Soc Adm Pharm. 2022;18(8):3453–62.

11. Badreldin HA, Atallah B. Global drug shortages due to COVID-19. Res Soc Adm Pharm. 2021;17(January):1946–9.

12. Watanabe JH, Kwon J, Nan B, Abeles SR, Jia S, Mehta SR. Medication use patterns in hospitalized patients with COVID-19 in California during the pandemic. JAMA Netw Open. 2021;4(5):e2110775–e2110775.

13. Galani A, Alygizakis N, Aalizadeh R, Kastritis E, Dimopoulos M-A, Thomaidis NS. Patterns of pharmaceuticals use during the first wave of COVID-19 pandemic in Athens, Greece as revealed by wastewater-based epidemiology. Sci Total Environ. 2021;798:149014.

14. Been F, Emke E, Matias J, Baz-Lomba JA, Boogaerts T, Castiglioni S, et al. Changes in drug use in European cities during early COVID-19 lockdowns–A snapshot from wastewater analysis. Environ Int. 2021;153:106540.

15. Reinstadler V, Ausweger V, Grabher A-L, Kreidl M, Huber S, Grander J, et al. Monitoring drug consumption in Innsbruck during coronavirus disease 2019 (COVID-19) lockdown by wastewater analysis. Sci Total Environ. 2021;757:144006.
Published
2023-04-30
How to Cite
NURHAYATI, Fitri et al. Drug Use Patterns during the COVID-19 Pandemic: A Case Study at Persahabatan General Hospital. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 21, n. 1, p. 115-120, apr. 2023. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/1396>. Date accessed: 25 apr. 2024. doi: https://doi.org/10.35814/jifi.v21i1.1396.
Citation Formats
Issue
Vol 21 No 1 (2023): JIFI
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.